Combination therapy ‘reduces risk of vascular events’ in PAD
A secondary trial analysis shows low-dose rivaroxaban plus aspirin benefit high-risk patients with lower extremity PAD, authors say
High-risk patients with symptomatic peripheral artery disease (PAD) of the legs are less likely to experience major vascular events if they are treated with a combination of rivaroxaban and aspirin versus aspirin alone, a secondary analysis of clinical trial results suggests.
The subanalysis was of a previously reported subgroup of patients with symptomatic lower extremity PAD enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies Study (COMPASS), which included 602 centres in 33 countries from 2013-20 and was funded by Bayer AG.
